New Biomarker Could Expand Immunotherapy Access for Colon and Rectal Cancer Patients
A newly identified biomarker, CTHRC1, is offering a potential breakthrough in predicting which patients with colon and rectal cancer are most likely to respond to immunotherapy. Currently, immunotherapy is only effective for around 5% of colon cancer patients, but this discovery could significantly broaden access to this potentially life-saving treatment.
Understanding the Role of CTHRC1 and the Tumor Microenvironment
The research, led by the Hospital del Mar Research Institute and IRB Barcelona, focuses on cancer-associated fibroblasts (CAFs) – connective tissue cells within tumors that aid their growth. Specifically, the study highlights CTHRC1(+) CAFs, cells expressing the CTHRC1 protein. Determining the presence of this protein in non-tumor cells within the cancer microenvironment could be key to establishing a patient’s prognosis.
“The tumour microenvironment plays a decisive role in the progression of colorectal cancer and in its response to treatments,” explains Dr. Eduard Batlle, ICREA researcher at IRB Barcelona and member of CIBERONC. “The identification of CTHRC1 as a TGF-beta-induced factor exemplifies how basic research can lead to clinically applicable biomarkers.”
How CTHRC1 Impacts Immunotherapy Response
The presence of CTHRC1(+) CAFs appears to indicate the state of immune cells within the tumor and their ability to fight cancer cells. This is crucial because immunotherapy relies on the body’s own immune system to attack the tumor. High levels of the CTHRC1 protein are linked to treatment resistance.
Dr. Clara Montagut, Head of Section of the Medical Oncology Department at Hospital del Mar, notes that this biomarker “improves the selection of patients who could potentially benefit from immunotherapy,” and could help guide therapeutic strategies.
Accessibility and Future Applications
One of the most promising aspects of this discovery is the accessibility of the testing method. The presence of CTHRC1(+) CAFs can be determined using immunohistochemistry tests, which are routinely performed in hospital pathology services. This means the biomarker can be readily integrated into existing clinical practice.
Dr. Mar Iglesias, researcher at HMRIB and CIBERONC and Head of the Pathology Department at Hospital del Mar, explains that the results “position CTHRC1(+) CAFs as a useful marker with the potential to be integrated into routine clinical practice in our services and hospitals, thereby helping to guide the selection of the most appropriate treatment for each patient.”
researchers suggest the potential applicability of this biomarker extends beyond colon and rectal cancer, potentially including breast and lung cancer.
Pro Tip:
Understanding your tumor microenvironment is becoming increasingly important in cancer treatment. Discuss biomarker testing with your oncologist to determine if it’s right for you.
FAQ
Q: What is immunotherapy?
A: Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.
Q: What are cancer-associated fibroblasts (CAFs)?
A: CAFs are connective tissue cells within tumors that can help them grow and spread.
Q: Is CTHRC1 testing widely available?
A: The test for CTHRC1 can be performed using standard immunohistochemistry tests, which are available in most hospital pathology labs.
Q: Could this biomarker help patients who aren’t currently eligible for immunotherapy?
A: Yes, the study suggests it could help identify patients who might benefit from immunotherapy even if they weren’t previously considered candidates.
Q: What is the role of TGF-beta in this process?
A: TGF-beta is a cytokine whose activity is measured by the new marker, and is associated with poorer disease outcomes.
Want to learn more about advancements in cancer treatment? Subscribe to our newsletter for the latest updates and research findings.
